Adaptimmune and Cryoport Collaboration Optimizes Supply Operations

October 14, 2019

Pharmaceutical Executive

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients,and Cryoport, Inc., a temperature-controlled logistics solutions company serving the life sciences industry, announced a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients,and Cryoport, Inc., a temperature-controlled logistics solutions company serving the life sciences industry, announced a 3-year agreement to ensure safe and fully monitored transport of Adaptimmune’s cell therapies.

This agreement with Cryoport will contribute to optimizing manufacturing and supply operations and other solutions, including investment in the latest systems and technology, digitization of the supply chain information, and improved communications with patients and healthcare professionals.